Zynext Ventures’ Post

First Investment...🚀 Zynext Ventures, the venture capital arm of Zydus Lifesciences, recently made its first investment in Promaxo, a company focused on advancing prostate cancer diagnosis and treatment. Promaxo has developed an innovative, minimally invasive imaging and biopsy system that uses advanced MRI technology. This system provides real-time, high-resolution imaging, aiming to improve the precision and effectiveness of prostate cancer procedures. This investment is part of Zynext Ventures' commitment to supporting advancements in healthcare technology and improving patient outcomes. Promaxo’s technology has the potential to make significant strides in prostate cancer care by enhancing accuracy and patient comfort. Stay tuned for more updates as Zynext Ventures continues to invest in and collaborate with companies driving innovation in Healthcare sector. #Investment #HealthcareInnovation #ProstateCancer #MedicalTechnology #VentureCapital #ZynextVentures #ZydusLifeSciences #Promaxo #InnovationInHealthcare

🚀 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐞𝐝: 2023'𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐆𝐚𝐦𝐞-𝐂𝐡𝐚𝐧𝐠𝐞𝐫𝐬! 🌟 Embarking on a new era, GE HealthCare, Johnson & Johnson, and Danaher have redefined the MedTech landscape through strategic spinoffs. 🌐✨ GE HealthCare, post-separation from General Electric, is blazing a trail in AI, elevating precision medicine in patient care. 💻💉 J&J took the plunge, spinning off its consumer brands into the dynamic Kenvue, raising a staggering $13.2 billion and honing its focus on pharmaceutical and medical device innovation. 📈💰 Meanwhile, Danaher, with its Veralto spinoff, stands tall as a powerhouse in life sciences and diagnostics. 🧪🔬 Hold tight for what's on the horizon in 2024! Baxter's kidney care spinoff and 3M's Solventum healthcare split promise to continue the MedTech revolution. 🔄💡 Medtronic, eyeing FY 2025, is set to divest in patient monitoring and respiratory interventions, steering towards high-growth arenas like atrial fibrillation and surgical robotics. 🚑🌐 Witness the evolution, witness the future. ✨ #MedTechRevolution #HealthInnovation #StrategicSpinoffs https://lnkd.in/gitjy3xw

Innovation is the lifeblood of any company and it is featured in Holly Scott’s #medtech rundown today. Holly’s curation of medtech news is how I start my Sunday morning. 🤘🏼 This week’s is chock-full of M&A, investment and innovation incubator news. I love incubators like MTI because they: ✅ sharpen the startups and their ideas ✅ cull the ideas that aren’t ready yet ✅ provide access to talent and cash Incubators like MTI help fuel the next generation of solutions. I think one of the coolest parts of corporate development is viewing startups and their ideas. 🤙🏼 I also think it is one of the hardest as you try not to be a Blockbuster and Netflix case study. 😉 —————- Social media lets others enter our personal and professional lives. It extends our reach and ability to access data, information and insights. People like Holly Scott, Joe Mullings, Matt Kaufman, Rick Voight, Bart Foster and Kevin Berchelmann influence me from thousands of miles away. Who do you follow? What do you learn? #leadership #changinglives #dothething

Three medtech spinoffs that reshaped the industry in 2023, and what to expect in 2024 Corporate spinoffs are reshaping the medical technology sector to enhance focus, increase revenue, and improve investor returns. Recent examples of spinoffs in the medtech landscape include: GE HealthCare: > Separated from General Electric, focusing on cost reduction and investing in machine learning for precision medicine. > Active in M&A, with collaborations and projects in AI-assisted ultrasound technology. Johnson & Johnson (J&J): > Spun off its consumer brands to create Kenvue, raising $13.2 billion. > Reported double-digit sales growth in medtech, restructuring slower-growth orthopedics, and acquiring heart pump maker Abiomed and Laminar, Inc.. Danaher Corporation: > Completed the spinoff of water testing and product identification operations into Veralto, becoming a pure play bioproduction, life science research, and diagnostics company. > Facing challenges like weaker #China demand but focusing on rising global demand for biologic medicines and acquisitions, such as the planned purchase of Abcam. Baxter International Inc.: > Announced plans to spin off renal care and acute therapies units into Vantive by 2024. > Completed the sale of its biopharma solutions business and reorganized remaining operations. 3M: > Progressing towards the spinoff of its healthcare business into Solventum by the first half of 2024. > Leadership team in place, focused on wound care, oral care, information systems, and biopharma filtration. Medtronic: > Plans to divest patient monitoring and respiratory interventions businesses in the first half of fiscal year 2025. > Aiming to boost growth through acquisitions in high-growth areas like #atrialfibrillation , #diabetes, #surgicalrobotics, and #structuralheart. > Medtronic's divestment follows a multiyear restructuring effort to improve financial performance, with a focus on core, high-growth markets. #surgicalrobotics #medtech #medtechdive https://lnkd.in/g_Smqa_j

CytoVeris is honored to be selected as a part of the 2024 MedTech Innovator cohort – MedTech Innovator is the world’s largest accelerator of medical technology companies: This was a particularly competitive year, with around 1,400 applying for approximately 65 spots in this year's final cohort.  Explore the full list of participating companies here: https://lnkd.in/eq8zbHmR We look forward working with industry experts to further our mission to bring enhanced tissue ID and cancer margin visualization to MIS & robotic procedures. #MedTechInnovator #CytoVeris #Cancersurgery #AI #Labelfree #autofluorescence #cancermargin#multispectral #intraoperativeimaging #Advancedvisualization #Precisionsurgery #metech #cancerdetection#enhancedimaging #roboticsurgery

3 medtech spinoffs that reshaped the industry in 2023, and what to expect next Corporate spinoffs are redefining the medical technology sector, as executives look to sharpen the focus of their operations, boost revenue and profit, and improve investor returns. While spinoffs tend to underperform the market in their first year, they outperform over a three- to five-year timeframe. GE Healthcare, Johnson & Johnson and Danaher completed transactions this year. Baxter, 3M and Medtronic are now on deck. #medtech #medtechspinoffs #spinoffs #medtechindustry

3 MedTech spinoffs that reshaped the industry in 2023, and what to expect next. Corporate spinoffs are redefining the medical technology sector, as executives look to sharpen the focus of their operations, boost revenue and profit, and improve investor returns. #MedicalDevice #MDR #MedTech

Imagine joining a MedTech startup focused on implantable medical devices. Among the many milestones, the ultimate goal is to bring such a device to the patient, and this is why First-in-Human Studies come into play. This journey is complex, requiring dedicated efforts from (but not limited to) development, regulatory, and financial perspectives, each with specific key milestones. For those new to the world of implantables, I've covered some of these topics in the latest article from the Kickigai newsletter. In this issue, some crucial aspects are covered regarding: - #Key Milestones to be reached before a green light to start the First in Human is achieved   - #Capital raised, with some examples from neurotech and why it is so important for the founders - #Timelines to get there - The #Next phases follow the first successful Pilot Studies. If you're curious, this is for you, and I'd be delighted to discuss it with you if you want to reach out. https://lnkd.in/d5qY_Stv Giammarco Pacifico #MedTech #Implantable #MedicalDevices #Startup

Great report by PitchBook on the #MedTech industry in Q2 2024 Overall positive momentum in the MedTech sector, with increasing investment and exit activity compared to the previous year, despite some challenges in the broader economic environment VC Investment Trends - Medtech VC investment held steady at $3.3 billion in Q2 2024, slightly down from $3.5 billion in Q1 - Through the first half of 2024, MedTech VC investment is on track to be about 20% higher compared to 2023 - Top #MedTech VC investment subsegments in Q2 included:  - Cardiovascular ($539.4 million)  - Other diagnostics ($403.2 million)   - Surgical implants ($287.1 million) Notable Deals and Exits - INSIGHTEC's $150 million late-stage VC round and BillionToOne's $130 million Series D were among the largest deals - Tempus AI had a headline-generating IPO in June, raising over $400 million - Other VC exits included acquisitions of BELKIN Vision, Attune Medical, and C2 Genomics Market Dynamics - $6.6 billion of VC exit value in the first half of 2024 exceeded the total for all of 2023, though still below 2021-2022 levels - PE deal activity is tracking slightly below 2023 levels, with 28 PE buyouts and 19 PE growth deals year-to-date - European Innovation Council Fund, SOSV, Alumni Ventures, and Arboretum Ventures have been among the most active VC investors in 2024 Company Spotlight Karius, a diagnostic company, recently raised a Series C round valuing the company at $185 million post-money - Company's liquid biopsy blood test for infectious diseases has seen strong growth, with over 40% top-line growth and 20,000+ annual test volume - Karius' market opportunity could potentially reach over $20 billion in the long-term

It is the era of spin-offs in MedTech, and MedTech Dive highlights three of the biggest from 2023, and three more coming in 2024. https://lnkd.in/eiG5nBym #medtech #spinoff